Division of Takeda Pharmaceutical Co. Ltd.
Latest From Baxalta Inc.
Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
While some companies rushed into gene therapy and exited after a single setback, Asklepios BioPharmaceutical quietly advanced its programs, identifying challenges and overcoming them one at a time. Now, it's ready to advance multiple programs into the clinic.
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Neurology, Nervous System
- Baxter BioScience
- North America
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
Ludwig N Hantson, PhD, Pres. & CEO
Robert J Hombach, EVP, CF & COO
John J Orloff, MD, EVP, Head, R&D & CSO
- Contact Info
Phone: (224) 940-2000
One Baxter Pkwy.
Deerfield, IL 60015
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.